OVID
NEUTRAL
$2.76
Live
Ovid Therapeutics Inc. · NASDAQ
Target $5.01
(+81.5%)
$0.27
52W Range
$3.1
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$416.84M
P/E
N/A
ROE
-17.5%
Profit margin
-240.1%
Debt/Equity
0.1
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
OVID presents a stark contrast between deterministic financial health and speculative growth potential, highlighted by a critical Piotroski F-Score of 0/9. While the company exhibits explosive revenue growth (844.70% YoY) and maintains a very strong liquidity position (Current Ratio 8.97), its operational efficiency is severely lacking with an operating margin of -1712.12%. The massive 1-year price surge of 865% is decoupled from current fundamentals, and insider selling by the CEO suggests a lack of confidence at current valuation levels. The stock remains a high-risk speculative play driven by analyst optimism rather than financial stability.
Key Strengths
Explosive YoY revenue growth of 844.70%
Exceptional short-term liquidity with a Current Ratio of 8.97
Very low leverage with a Debt/Equity ratio of 0.10
Strong analyst consensus with a 'strong_buy' rating and $5.01 target
Significant 1-year price momentum (+865%)
Key Risks
Critical financial health failure indicated by a 0/9 Piotroski F-Score
Extreme valuation premium with a Price/Sales ratio of 57.48
Severe operational losses with a -1712.12% operating margin
Bearish insider sentiment including sales by the CEO
High volatility typical of clinical-stage biotechnology firms
AI Fair Value Estimate
Based on comprehensive analysis
$4.0
+44.9% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
36
Weak
20
85
60
15
0
AI Verdict
Speculative Growth
Key drivers: Revenue acceleration, Cash runway, Fundamental deterioration (F-Score), Valuation disconnect
Confidence
85%
Value
20/100
Trades at a massive premium to sales; valuation is based entirely on future pipeline success.
Positives
- Price/Book is relatively moderate at 2.75
Watchpoints
- P/S ratio of 57.48 is unsustainable
- No Graham Number due to lack of earnings
Future
85/100
Growth rates are exceptional, though starting from a very low base.
Positives
- Hyper-growth in revenue
- Positive EPS surprise trend in recent quarters
- Strong analyst price targets
Watchpoints
- Dependence on binary clinical/regulatory outcomes
Past
60/100
Recent performance is bullish, but long-term trend shows historical struggle.
Positives
- Massive 1-year price appreciation
- Consistent ability to beat earnings estimates recently
Watchpoints
- Long-term 5-year return is negative (-27%)
Health
15/100
Strong balance sheet (cash) but failing operational health metrics.
Positives
- Low debt levels
- High current ratio
Watchpoints
- Piotroski F-Score of 0/9 indicates severe fundamental weakness
- Deeply negative profit and operating margins
Dividend
0/100
Typical for biotech; all capital is reinvested or consumed by R&D.
Positives
No standout positives identified.
Watchpoints
- No dividend history
- Zero payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.76
Analyst Target
$5.01
Upside/Downside
+81.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OVID and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OVID
Ovid Therapeutics Inc.
Primary
|
-27.0% | -11.8% | +865.0% | +67.3% | +41.5% | +6.2% |
|
AUNA
Auna SA
Peer
|
-41.0% | -41.0% | -30.8% | -9.7% | +21.7% | +22.2% |
|
AGL
agilon health, inc.
Peer
|
-96.8% | -95.0% | -73.1% | -51.9% | +41.4% | -2.8% |
|
ACRS
Aclaris Therapeutics, Inc.
Peer
|
-85.2% | -56.5% | +126.9% | +81.5% | +4.4% | +15.7% |
|
KIDS
OrthoPediatrics Corp.
Peer
|
-67.6% | -67.3% | -25.3% | -2.0% | -10.3% | -0.6% |
OVI
Ovid Therapeutics Inc.
Primary
5Y
-27.0%
3Y
-11.8%
1Y
+865.0%
6M
+67.3%
1M
+41.5%
1W
+6.2%
AUN
Auna SA
Peer
5Y
-41.0%
3Y
-41.0%
1Y
-30.8%
6M
-9.7%
1M
+21.7%
1W
+22.2%
AGL
agilon health, inc.
Peer
5Y
-96.8%
3Y
-95.0%
1Y
-73.1%
6M
-51.9%
1M
+41.4%
1W
-2.8%
ACR
Aclaris Therapeutics, Inc.
Peer
5Y
-85.2%
3Y
-56.5%
1Y
+126.9%
6M
+81.5%
1M
+4.4%
1W
+15.7%
KID
OrthoPediatrics Corp.
Peer
5Y
-67.6%
3Y
-67.3%
1Y
-25.3%
6M
-2.0%
1M
-10.3%
1W
-0.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-5.89
PEG Ratio
N/A
P/B Ratio
2.75
P/S Ratio
57.48
EV/Revenue
42.44
EV/EBITDA
-7.3
Market Cap
$416.84M
Profitability
Profit margins and return metrics
Profit Margin
-240.13%
Operating Margin
-1712.12%
Gross Margin
100.0%
ROE
-17.51%
ROA
-21.82%
Growth
Revenue and earnings growth rates
Revenue Growth
+844.7%
Earnings Growth
N/A
Q/Q Revenue Growth
+844.74%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.1
Low debt
Current Ratio
8.97
Strong
Quick Ratio
8.4
Excellent
Cash/Share
$0.53
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-1712.1%
Net Margin
1345.8%
Total Assets
$0.2B
Liabilities
$0.0B
Equity
$0.1B
Debt/Equity
0.16x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-12
$N/A
2026-03-18
$0.06
+161.2% surprise
2025-11-12
$-0.17
-14.9% surprise
2025-08-13
$-0.06
+59.3% surprise
Healthcare Sector Comparison
Comparing OVID against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-17.51%
This Stock
vs
-100.15%
Sector Avg
-82.5%
(Below Avg)
Profit Margin
-240.13%
This Stock
vs
-13.63%
Sector Avg
+1661.9%
(Superior)
Debt to Equity
0.1
This Stock
vs
3.22
Sector Avg
-96.8%
(Less Debt)
Revenue Growth
844.7%
This Stock
vs
121.05%
Sector Avg
+597.8%
(Fast Growth)
Current Ratio
8.97
This Stock
vs
4.55
Sector Avg
+97.2%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OVID
Ovid Therapeutics Inc.
|
NEUTRAL | $416.84M | - | -17.5% | -240.1% | $2.76 | |
|
AUNA
Auna SA
|
NEUTRAL | $418.91M | 5.78 | 11.4% | 4.3% | $5.66 | Compare |
|
AGL
agilon health, inc.
|
BEARISH | $410.85M | - | -73.3% | -5.2% | $0.99 | Compare |
|
ACRS
Aclaris Therapeutics, Inc.
|
BEARISH | $428.65M | - | -50.2% | -% | $3.54 | Compare |
|
KIDS
OrthoPediatrics Corp.
|
BEARISH | $403.7M | - | -11.3% | -16.8% | $15.97 | Compare |
OVID
Ovid Therapeutics Inc.
NEUTRAL
Mkt Cap
$417M
P/E
-
ROE
-17.5%
Price
$2.76
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-07 | FRIEDMAN BART | Director | Stock Award | 8,789 | $22,500 |
| 2026-04-07 | FITZGERALD KEVIN JOSEPH | Director | Stock Award | 17,578 | $45,000 |
| 2026-04-07 | PAPADOPOULOS STELIOS B | Director | Stock Award | 17,578 | $45,000 |
| 2026-03-23 | LEVIN JEREMY M | Officer and Director | Option Exercise | 47,333 | $66,266 |
| 2026-02-26 | RONA JEFFREY A | Officer | Stock Award | 68,125 | - |
| 2026-02-23 | RONA JEFFREY A | Officer | Sale | 8,541 | $12,384 |
| 2026-02-23 | ALEXANDER MARGARET A. | Chief Executive Officer | Sale | 11,656 | $16,901 |
| 2025-12-15 | LEVIN JEREMY M | Chief Executive Officer | Stock Award | 71,000 | - |
| 2025-12-08 | TAKEDA PHARMACEUTICAL CO., LTD. | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 1,250,000 | - |
FRIEDMAN BART
Director
2026-04-07
8,789 shares
·
$22,500
FITZGERALD KEVIN JOSEPH
Director
2026-04-07
17,578 shares
·
$45,000
PAPADOPOULOS STELIOS B
Director
2026-04-07
17,578 shares
·
$45,000
LEVIN JEREMY M
Officer and Director
2026-03-23
47,333 shares
·
$66,266
RONA JEFFREY A
Officer
2026-02-26
68,125 shares
RONA JEFFREY A
Officer
2026-02-23
8,541 shares
·
$12,384
ALEXANDER MARGARET A.
Chief Executive Officer
2026-02-23
11,656 shares
·
$16,901
LEVIN JEREMY M
Chief Executive Officer
2025-12-15
71,000 shares
TAKEDA PHARMACEUTICAL CO., LTD.
Beneficial Owner of more than 10% of a Class of Security
2025-12-08
1,250,000 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
9 analysts
Wedbush
2026-04-15
Outperform
Outperform
HC Wainwright & Co.
2026-04-09
Buy
Buy
BTIG
2026-03-26
Buy
Buy
Wedbush
2026-03-20
Outperform
Outperform
LifeSci Capital
2025-12-22
Outperform
HC Wainwright & Co.
2025-12-22
Buy
Buy
Roth Capital
2025-12-11
Buy
HC Wainwright & Co.
2025-11-24
Buy
Buy
Leerink Partners
2025-11-17
Outperform
Past News Coverage
Recent headlines mentioning OVID from our newsroom.
Newest → oldest
No matching news yet.